Breast Cancer and Hormone-Related Therapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 20 November 2024 | Viewed by 22432
Special Issue Editor
Special Issue Information
Dear Colleagues,
Breast cancer remains the most common malignancy in women and over 70% of all breast tumors are initially characterized as being “hormonally sensitive” based on expression of estrogen receptor alpha (ERα). ERα positive tumors are known to be driven by estrogens and, as such, numerous therapies have been developed to either directly target ERα (such as tamoxifen and fulvestrant) or to suppress the production of estrogen throughout the body through the use of ovarian function suppression and/or aromatase inhibitors. More recently, a newer class of drugs known as CDK4/6 inhibitors have demonstrated profound activity in the metastatic setting and are now commonly used in combination with aromatase inhibitors as a first line therapy for patients with recurrent ERα positive tumors.
In addition to ERα, a number of other hormone activated transcription factors, including ERβ, progesterone receptor, androgen receptor, and glucocorticoid receptor, have been shown to be expressed in breast cancer, and substantial efforts have been made to determine the contribution of these factors in breast cancer development, progression, and treatment. As a result of these efforts, and the world-wide uptake of many different forms of hormonal therapy, breast cancer has become a more manageable disease. However, with the significant extension of lifespan comes the increased probability of treatment failure, disease recurrence, and the diminution in the efficacy of additional hormone-based treatment strategies.
This Special Issue relates to emerging hormonal therapies, both for newly diagnosed and resistant forms of breast cancer, the molecular mechanisms by which such therapies elicit their anti-cancer effects and the cellular processes that are ultimately responsible for treatment failure.
Dr. John R. Hawse
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- breast cancer
- estrogen receptor
- hormone activated transcription factors
- hormonal therapy
- molecular mechanisms
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
Planned Papers
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Triple negative breast cancer and bazedoxifen
Authors: Rosa Sirianni
Affiliation: Università della Calabria, Cosenza, Italy
Title: hormonal treatment options in metastatic breast cancer after progression to a first line with cyclin inhibitors
Authors: Serafin Morales
Affiliation: HOSPITAL UNIVERSITARI ARNAU DE VILANOVA DE LLEIDA
Title: related to an exciting concept of photodynamic therapy targeted at hormone-dependent brat cancer cells
Authors: Marek Murias
Affiliation: Poznan University of Medical Sciences